Key developments in stem cell therapy in cardiology

Regenerative Medicine

Volumn 7, Issue 6 SUPPL., 2012, Pages 17-24

  Schulman, Ivonne H ^a,b   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Miami Veterans Affairs Healthcare System   (United States)

Author keywords

Cardiac stem cell; Cell transplantation; Heart failure; Ischemic heart disease; Mesenchymal stem cell; Myocardial infarction

Indexed keywords

ACUTE HEART INFARCTION; ARTICLE; BONE MARROW TRANSPLANTATION; CARDIAC IMAGING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL INTERACTION; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; PATIENT SAFETY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84870685387     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.80     Document Type: Article

References (43)

1. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 123(4), e18-e209 (2011).
2. Williams AR, Trachtenberg B, Velazquez DL et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ. Res. 108(7), 792-796 (2011).
3. Suncion VY, Schulman IH, Hare J. Concise review: the role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy. Stem Cells Transl. Med. 2(1), 29-35 (2012).
4. Karantalis V, Balkan W, Schulman IH, Hatzistergos K, Hare JM. Cell-based therapy for prevention and reversal of myocardial remodeling. Am. J. Physiol. Heart Circ. Physiol. 303(3), H256-H270 (2012).
5. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv. Cancer Res. 100, 133-158 (2008).
6. Zhu WZ, Hauch KD, Xu C, Laflamme MA. Human embryonic stem cells and cardiac repair. Transplant Rev. (Orlando) 23(1), 53-68 (2009).
7. Wernig M, Meissner A, Foreman R et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448(7151), 318-324 (2007).
8. Ieda M, Fu JD, Delgado-Olguin P et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142(3), 375-386 (2010).
9. Mushtaq M, Oskouei BN, Hare JM. Cell therapy for heart disease: to genetically modify or not, that is the question. Circ. Res. 108(4), 398-401 (2011).
10. Kanashiro-Takeuchi RM, Schulman IH, Hare JM. Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J. Mol. Cell. Cardiol. 51(4), 619-625 (2011).
11. Leistner DM, Fischer-Rasokat U, Honold J et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCAREAMI): final 5-year results suggest longterm safety and efficacy. Clin. Res. Cardiol. 100(10), 925-934 (2011).
12. Schaefer A, Zwadlo C, Fuchs M et al. Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial - an echocardiographic study. Eur. J. Echocardiogr. 11(2), 165-171 (2010).
13. Traverse JH, Henry TD, Ellis SG et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 306(19), 2110-2119 (2011).
14. Hare JM. Bone marrow therapy for myocardial infarction. JAMA 306(19), 2156-2157 (2011).
15. Perin EC, Willerson JT, Pepine CJ et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUSCCTRN trial. JAMA 307(16), 1717-1726 (2012).
16. Traverse JH, Henry TD, Vaughan DE et al. Rationale and design for TIME: a Phase II, randomized, double-blind, placebocontrolled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am. Heart J. 158(3), 356-363 (2009).
17. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ. Res. 109(8), 923-940 (2011).
18. Mazo M, Arana M, Pelacho B, Prosper F. Mesenchymal stem cells and cardiovascular disease: a bench to bedside roadmap. Stem Cells Int. 175979 (2012).
19. Bolli R, Chugh AR, D'amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised Phase 1 trial. Lancet 378(9806), 1847-1857 (2011).
20. Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised Phase 1 trial. Lancet 379(9819), 895-904 (2012).
21. Hatzistergos KE, Quevedo H, Oskouei BN et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ. Res. 107(7), 913-922 (2010).
22. Williams AR, Hatzistergos KE, Carvalho D et al. Synergistic effect of human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and restore cardiac function. Circulation 124(21), Abstract A13079 (2011).
23. Jeevanantham V, Butler M, Saad A, Abdel- Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 126(5), 551-568 (2012).
24. Quyyumi AA, Waller EK, Murrow J et al. CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am. Heart J. 161(1), 98-105 (2011).
25. Duckers E. Freshly adipose-derived stem cell in acute myocardial infarction. The APOLLO Trial. Presented at: Seventh International Symposium on Stem Cell Therapy and Cardiovascular Innovations. Madrid, Spain, 6-7 May 2010.
26. Losordo DW, Henry TD, Davidson C et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ. Res. 109(4), 428-436 (2011).
27. Vrtovec B, Poglajen G, Sever M et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J. Card Fail 17(4), 272-281 (2011).
28. Quevedo HC, Hatzistergos KE, Oskouei BN et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc. Natl Acad. Sci. USA 106(33), 14022-14027 (2009).
29. Schuleri KH, Feigenbaum GS, Centola M et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur. Heart J. 30(22), 2722-2732 (2009).
30. Hare JM, Velazquez DL, Zambrano JP et al. Randomized comparison of allogeneic vs autologous mesenchymal stem cells in patients with ischemic cardiomyopathy. Circulation (Abstract, in press) (2012).
31. Perin E, Fernandez-Aviles, F. The PRECISE Trial. Presented at: Seventh International Symposium on Stem Cell Therapy and Cardiovascular Innovation. Madrid, Spain, 6-7 May 2010.
32. Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114(6), 763-776 (2003).
33. Smith RR, Barile L, Cho HC et al. Regenerative potential of cardiospherederived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 115(7), 896-908 (2007).
34. Barile L, Chimenti I, Gaetani R et al. Cardiac stem cells: isolation, expansion and experimental use for myocardial regeneration. Nat. Clin. Pract. Cardiovasc. Med. 4(Suppl. 1), S9-S14 (2007).
35. Giannotti G, Doerries C, Mocharla PS et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 55(6), 1389-1397 (2010).
36. Fischer KM, Cottage CT, Wu W et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 120(21), 2077-2087 (2009).
37. Shujia J, Haider HK, Idris NM, Lu G, Ashraf M. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc. Res. 77(3), 525-533 (2008).
38. Li W, Ma N, Ong LL et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25(8), 2118-2127 (2007).
39. Cho J, Zhai P, Maejima Y, Sadoshima J. Myocardial injection with GSK-3betaoverexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction. Circ. Res. 108(4), 478-489 (2011).
40. Williams A, Hatzistergos K, Carvalho D et al. Synergistic effect of human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and restore cardiac function. Circulation 124, A13079 (2011).
41. Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernandez-Hernando C, Suarez Y. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler. Thromb. Vasc. Biol. 31(11), 2595-2606 (2011).
42. Song K, Nam Y-J, Luo X et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485(7400), 599-604 (2012).
43. Templin C, Zweigerdt R, Schwanke K et al. Transplantation and tracking of human induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment and distribution by hybrid SPECT-CT imaging of sodium iodide symporter trangene expression. Circulation 126(4), 430-439 (2012).